Candriam S.C.A. Summit Therapeutics Inc. Transaction History
Candriam S.C.A.
- $16.9 Billion
- Q4 2024
A detailed history of Candriam S.C.A. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 842,551 shares of SMMT stock, worth $17.9 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
842,551
Previous 850,403
0.92%
Holding current value
$17.9 Million
Previous $18.6 Million
19.25%
% of portfolio
0.09%
Previous 0.11%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
231Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$520 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$248 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$168 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$139 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$119 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.28B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...